



February 13, 2026

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics Inc. (The Company) announces that the non-operating income, non-operating expenses and extraordinary losses were recorded in the first nine months of the fiscal year 2026/03. The details are as follows:

1. Non-operating income

The Company has recorded subsidy income of 53,311 thousand yen, foreign exchange gains of 8,832 thousand yen, and interest income of 3,392 thousand yen respectively as non-operating income.

2. Non-operating expenses

The Company has recorded share issuance costs 1,726 thousand yen as non-operating expenses.

3. Extraordinary losses

The Company has recorded impairment losses of 37,006 thousand yen for its non-current assets in accordance with the Accounting Standard for Impairment of Fixed Assets as extraordinary losses.

4. Impact on financial results

The above items have been fully reflected in the “Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026” announced today.

END